ESR1 gene mutations consist one of the resistant mechanisms to endocrine therapies for ER-positive metastatic breast cancer patients37 and have been also detected in single CTCs exposing important information about their mutational heterogeneity and subsequently for the resistance to therapies38,39. The gene discussed is ESR1; the disease is breast carcinoma.